Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2009BloodOpen Access

How I monitor residual disease in chronic myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJerald P. RadichThe Wistar Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jerald P. Radich (2009) studied this question.

synapsesocial.com/papers/6a176003cf02a40e68b3f582https://doi.org/10.1182/blood-2009-02-163485
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cyclic oscillations of leucocyte counts in chronic myeloid leukaemia1991 · 5 citations
  2. 2Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia1986 · 555 citations
  3. 3Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods2007 · 159 citations
  4. 4BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML2006 · 125 citations
  5. 5Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials2008 · 392 citations